Press release
October 18, 2016
Corindus Vascular Robotics to Feature CorPath®System at TCT 2016 Breakfast Symposium

Martin Leon, M.D. to chair session focused on building successful vascular robotic programs and the future vision for cardiovascular robotics

WALTHAM, MA - October 18, 2016Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, will sponsor a breakfast symposium entitled "Robotic Therapy – Current Applications & Future Vision" on Monday, October 31 at 7:00 a.m. at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2016 conference. TCT, the largest educational meeting in the world specializing in interventional cardiovascular medicine, will take place from Saturday, October 29 through Wednesday, November 2 at the Walter E. Washington Convention Center in Washington, D.C.

The breakfast symposium will be chaired by Martin B. Leon, M.D., Director, Center for Interventional Vascular Therapy NewYork-Presbyterian Hospital/Columbia University Medical Center and Chairman Emeritus of the Cardiovascular Research Foundation (CRF), and will also feature a faculty of leading interventional cardiologists. An audience discussion and Q&A session will follow the presentations.

"I'm excited to present the vision of where robotic therapy fits in the future of the cath lab. Robotics may become very important to protect practitioners and to reduce variability and improve clinical outcomes," said Dr. Leon.

Mark Toland, Corindus President and CEO, stated, "As adoption of robotic therapy in PCI continues to grow, we see that success comes when facilities build comprehensive robotic programs to maximize the benefit of cardiovascular robotics. This symposium will educate attendees on how current users have successfully developed programs and outline the future that we see for robotics in the cath lab."

"Robotic Therapy – Current Applications & Future Vision" will feature the following speakers and topics:

  • "Robotic Therapy: Past, Present & Future" with Martin B. Leon, M.D.
  • "Building a Successful Vascular Robotic Program" with Gregory A. Helmer, M.D., University of Minnesota & Fairview Hospitals; Edina, MN
  • "Evidence for Robotic Therapy: From Cath Lab Wellness to Patient Benefits" with Ryan D. Madder, M.D., Frederik Meijer Heart & Vascular Institute, Spectrum Health; Grand Rapids, MI
  • "Complex Robotic Intervention" with Ehtisham Mahmud, M.D., UC San Diego School of Medicine; La Jolla, CA

Corindus' CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention procedures while protecting medical professionals from radiation exposure occurring in hospital cath labs. By bringing robotic precision to complex, radial, coronary and peripheral procedures, the CorPath System helps optimize clinical outcomes and minimize costs associated with manual procedures.

Space for the symposium is limited. For more information and to register for the symposium, visit

To take advantage of an exclusive opportunity to use the CorPath System with an advanced simulator, register here and visit Corindus at booth #1322 at TCT 2016.


About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
close the window

Please complete the form below in order to download the content.

close the window

Please complete the form below in order to download the content.

close the window

Please fill out this brief form to subscribe to our email newsletter. By submitting this form, I consent to receive email communications from Corindus.

close the window

Please complete the form below and a member of our Clinical team will contact you.

close the window

Please complete the form below in order to download the content.

close the window

The page you wish to view contains content that is not available in all regions. Please select your region.

close the window